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Abstract
Research focus: Skin injuries are evolving as an epidemic issue. Chronic skin lesion is 
a globally widespread disease, often referred to as a “wound difficult to heal” and one 
which has a strong impact on both overall health and quality of life. Genetic and clinical 
variables, such as diabetes, smoking and inflammatory/immunological pathologies, are 
among the important risk factors limiting the regenerative powers of many therapeutic 
applications. Therefore, optimisation of current clinical strategies is critical. Experimental 
research: Here we summarise the field’s current state by focusing on the use of stem-cell 
therapeutic applications in wound healing, placing considerable emphasis on current clini-
cal approaches being developed at Rome’s Sapienza University. These involve protocols for 
the ex vivo expansion of adipose tissue-derived mesenchyme stem cells using a patented 
GMP-compliant platelet lysate, Mesengen™, and cellular and acellular dermal substitutes. 
A combination of multiple strategies, including genetic modifications of stem cells, biomi-
metic scaffolds or novel vehicles like nanoparticles, is also discussed as future approaches. 
Case studies: Here we present a report portraying our clinical experience of the treat-
ment of chronic phlebostatic ulcers. The aim of the study reported here was to evaluate 
the effectiveness of treatment with dermal substitutes of cutaneous lesions originating 
from chronic venous insufficiency, therapy which took into consideration parameters 
such as the reduction of wound size and the improvement of quality of life. Chronic skin 
lesion, a globally widespread disease, is often referred to as a “difficult wound” and has a 
strong impact on both overall health and quality of life. The difficulties encountered when 
seeking to heal this ailment have led to a quest for and development of new therapeutic 
approaches, including dermal substitutes. We can subdivide these into acellular matrices, 
such as Integra and Hyalomatrix, and cell therapies such as platelet concentrate and mes-
enchyme cell concentrate. Results: In all the patients treated, elements of improvement 
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were observed: the appearance on the wound bed of small islands of granulation tissue, 
superficialization of the bottom of the ulcer and a growth of marginal tissue. During the 
first 30 days, a reduction in more than 25% of the area of the lesion and a reduction in 
more than 50% at the end of the observation period were recorded in 10 of the patients 
who underwent preliminary surgical treatment out of the 13 subjects included in the study 
sample. On the whole, at the end of the observation period, we witnessed an average 57% 
decrease in the lesion in all the patients; furthermore, during the treatment period, there 
was a gradual reduction in pain, measured using the NRS numerical scale. An overall 
average reduction in pain of four points on the NRS numerical scale was achieved. At the 
end of the 8-week evaluation period, the majority of the patients reported an improvement 
in the quality of their lives, since, in addition to the reduction of spontaneous pain, there 
was a diminution of pruritus, secretions—often malodorous and capable of affecting social 
life negatively—with recovery of functional capacity and almost complete recovery of 
habitual daily activities. During the period of treatment, no superinfections of the wounds 
or secondary complications related to the use of the various products were detected. Main 
conclusions: The numerous technological opportunities provided by regenerative medi-
cine—including advanced dressings and dermal substitutes—if applied correctly, in com-
pliance with a multidisciplinary approach where necessary, seem to offer advantages not 
only in terms of clinical efficacy and patient life quality but also in terms, it would appear, 
of healthcare costs, an aspect which should not be either overlooked or underestimated.
Keywords: wound healing, skin lesion, regenerative medicine, dermal substitutes, 
phlebostatic ulcers
1. Introduction
The management of scarring in chronic wounds represents one of the most relevant clinical 
problems affecting healthcare in the United States and in Europe [1]. Scars can cause severe 
physical damage, resulting, predominantly, in damage to the skin.
This kind of lesion causes loss of cutaneous substance, varies in size and involves loss of 
underlying tissue as well; this kind of lesion is often defined as “difficult” because it fails 
to heal spontaneously or achieve speedy and complete recovery. Acute or chronic wounds 
of this type are due to multifactor pathogeneses, and their healing is impeded, as a rule, by 
persistent local or systemic factors which favour chronicisation.
Medical-surgical treatment of these so-called “difficult” lesions represents a constantly 
increasing social-health issue, a “silent epidemic” affecting large sectors of the world’s popu-
lation, one which, at present, concerns about 2,000,000 Italians; these numbers are destined to 
grow further due not only to diverse risk factors but also to the phenomenon of ageing [2, 3].
Subjects with pre-existing diseases are of particular concern, as treatment and resolution of 
injury frequently require long-term care. Healing is often compromised in similar individuals 
because of the presence of diabetes, the metabolic syndrome, chronic renal failure and ageing 
[4] since the ability to rapidly re-epithelialise and revascularise injured tissue is impaired. In 
some cases, the evolution of the lesion is correlated to the root-cause pathology, as, in particu-
lar, in the case of “immunohaematological” ulcers.
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Both clinical and genetic features of individual patients must be considered when addressing 
wound healing, as well as variations in medical responses based on the type of chemical tools 
employed and the nature and extent of the injured area. In fact, large wounds, under either 
adverse local or systemic conditions, respond poorly to treatment and can frequently reopen.
It is calculated that about 10% of the population is likely to develop a chronic lesion during its 
lifetime, leading to discomfort (pain, reduced hygiene, sleep disturbance), loss of autonomy, 
need of assistance and frequent hospitalisation, with considerable deterioration of the quality 
of life (QoL) due, among other things, to embarrassment, social isolation, compromisation of 
employability, monetary costs, anxiety-depressive syndromes [5] as well as a mortality rate 
of 2.5% [6, 7]. A chronic dermal lesion means having to live with a persistent, enduring and 
treatment-resistant wound, which has a significant impact on the overall health and quality 
of life of patients, members of their families and caregivers.
Chronic venous insufficiency is responsible for 80% of the ulcers affecting the lower limbs, a 
sequela constituting one of the gravest complications encountered by CVIs [2].
As people grow older, venous ulcers begin to constitute a serious health problem, consider-
ing the fact that 4% of people aged over 65 suffer from them. This renders the whole issue 
highly topical while making possible therapeutic treatments within the ambit of regenerative 
medicine of considerable interest.
A number of strategies have been developed recently to treat dermal wounds resulting from 
chemical exposure. One of the most efficient methods used to reduce bacterial load and the 
incidence of sepsis is debridement of the wound [8]. Cleansing agents and topical antibiotics 
are also useful when seeking to reduce microbial growth and invasive infection [9].
Current literature contains numerous studies [10–12], which underline the diffusion of medi-
cation considered “advanced” and capable of producing improved clinical and economic out-
comes associated with the healing of similar lesions. The notion “advanced” implies not only 
the use of particular products and medications, surpassing the therapeutic concept of keeping 
the ulcer in a “dry” environment and leaving medication on the lesion for lengthy periods of 
time, but also means changing wound management substantially. Advanced methodologies 
seem to lead to a diminution of the number of medication sessions required compared to 
those prescribed by traditional approaches and, theoretically speaking, a reduction in overall 
healing time, which also spells a reduction in costs. We have expressed ourselves in dubita-
tive terms here because many factors of a logistic and not simply clinical nature, capable of 
impacting negatively or positively on the treatment opted for, are involved and can contribute 
to the success or failure of the therapy. One of the factors—common to acute and chronic 
lesions and, therefore, regardless of aetiopathogenesis—which is capable of having a positive 
impact on regenerative therapy is appropriate “wound bed preparation” (WBP). “Wound bed 
preparation” involves a detailed, coordinated and sometimes multidisciplinary management 
of the lesion aimed at removing all the factors, which may hamper tissue regeneration, while 
favouring endogenous healing, promoting cellular proliferation and the reparatory processes 
“triggered” by the products applied. This concept, no longer considered recent, has signifi-
cantly affected the management of chronic cutaneous wounds and the results obtained.
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In order to outline the principles of WBP more precisely, the English acronym TIME (tissue, 
infection or inflammation, moisture imbalance, epidermal margin) is used. TIME breaks up 
what is actually a single therapeutic process into parts, indicating the fundamental aspects to 
be dealt with during preparation of the wound bed.
In lesion management, WBP permits definitive elimination of all the elements that may hinder 
the development of granulation tissue, thus laying the foundations for effective use of innova-
tive therapeutic tools. The purpose of advanced dressing is to create an environment ideal for 
proliferative cicatrisation processes, for the isolation of the wound from traumatic and infec-
tious agents, while improving the state of the bottom of the wound and promoting maximum 
possible tropism of the margins and the periwound skin.
Additionally, treatment of the wound with autologous leukocytes seeded in a proangio-
genic matrix and enriched with a platelet concentrate preparation has been reported to 
induce the release of growth factors, cytokines and chemokines, thus increasing the in situ 
recruitment of endothelial precursor cells and promoting the resolution of microbial infec-
tions [13]. Despite these improvements, treatment of dermal wounds has not always pro-
duced positive outcomes. Major drawbacks include the fact that the skin is a highly complex 
organ and is, therefore, difficult to reconstruct after injury. In actual fact, the physiological 
re-epithelialisation phase is a multistep process involving several cell types and molecular 
mechanisms, and the presence of a favourable environment for bacterial colonisation is 
highly undesirable [14, 15]. As a consequence, most current treatments have been palliative 
only, aiming mainly at accelerating healing time and limiting additional clinical complica-
tions caused by fortuitous bacterial infection. Therefore, alternative strategies are required 
to balance the treatment of patients, economic costs and the safety of civilians.
The main aim of regenerative medicine is to repair organs and tissues that have been dam-
aged by pathological events and/or trauma and/or ageing in order to restore or improve their 
biological functions. It is a multidisciplinary field undergoing rapid growth and involving 
the medical, humanistic and engineering sciences, a field which endeavours to develop func-
tional cells and substitute tissues or organs with a view to repairing, replacing or improving 
the biological functions lost due to congenital anomalies, trauma and illness or as a result of 
ageing. The increase in average life expectancy has led, actually, to the need to protract the 
time people spend in active employment and has made the physical and mental efficiency of 
older subjects mandatory, but it also implies an inevitable rise in incidences of neoplasms and 
pathologies that cannot always be cured by the therapies available at present. From this stems 
the need to develop therapies capable of replacing or regenerating organs damaged by patho-
logical processes or traumas. Referring specifically to the present text, regenerative medicine 
can solve the problem of chronic vascular ulcers. Some lesions can benefit particularly from 
regenerative, cellulated and acellulated materials as well as biochemical supports (scaffolds) 
used to “trigger” granulation, repair tissue and, therefore, cover wounds.
Scaffolds, according to the definition of tissue engineering provided by the National Science, 
are materials that can best attend to the restoration, maintenance and improvement of the 
function of tissues, playing a unique role in their repair and above all, in their regeneration 
[16–18]. Scaffolds provide an appropriate platform for the essential provision of various 
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factors associated with cell survival, proliferation and differentiation [19]. They can consist 
in synthetic or absorbable polymeric materials present in nature which may be biological, 
degradable or nondegradable.
The four main approaches to scaffolding include the use of ECM-secreting cell sheets; precon-
stituted porous scaffolds of synthetic, natural and biodegradable biomaterials; decellularised 
ECM scaffolds and cells enveloped in hydrogel [20].
In the field of surface-tissue regeneration, numerous grafts based on acellular dermal and 
epidermal scaffolds have been tested, using natural and synthetic polymers, or a combination 
of both, described as “effective substitutes for wound healing”.
Another important area where regenerative medicine is applied is that of cell therapy, which 
is based on the autologous cell suspension (SCAut) technique, that is, the exploitation of cells 
taken from the patients themselves.
A new chapter in the history of regenerative medicine, though still very controversial and 
limited to specifically clinical application, is that of tissue bioengineering, that is, the use of 
totipotent, pluripotent and unipotent cells, potentially capable of originating, respectively, any 
kind of tissue, a wide range of tissues and a sole cell line; the cells chosen for cropping can 
come from autologous, homologous and heterologous samples. The isolation, culture and mat-
uration of stem cells are recurred to with a view to replacing damaged tissue. Among the first 
mechanical and chemical processing techniques used is the in vitro cultivation of the epidermis 
using the “feeder-layer” methodology proposed by Rheinwald J.G. and Green H. in 1977 and 
the grafting of laminates of expanded in vitro keratinocytes or keratinocyte suspensions onto 
de-epidermised human dermis (DED) introduced by Cuono C.B. in 1987. The potential use of 
different types of stem cells for regenerative skin-lesion repair has recently received consider-
able attention [21]. “Difficult” or “stubborn” chronic wounds, characterised by extensive loss 
of substance and an enduring clinical history of healing and recurrence, represent one of the 
fields where the bioengineering of tissue may be applied and one of the discipline’s main areas 
of challenge.
The cell lines which arouse the greatest interest at the moment are those taken from the 
embryo, the foetus and the umbilical cord as well as a number of adult cells like adipose-
tissue-derived mesenchymal stem cells.
Several protocols have been established aimed at ensuring the resolution of wound issues by 
targeting different phases of the healing process, namely, control of inflammation in a suitable 
microenvironment, enhancement of stem-cell engraftment after implantation, efficient and 
terminal transdifferentiation of progenitors towards dermal lineages and the reconstruction of 
the vasculature system surrounding the wound [22, 23]. Mesenchymal stem cells (MSCs) have 
recently been proposed as a promising solution capable of enhancing the re-epithelialisation 
phase [24]. Studies using mouse models have shown that the intradermal injection of human 
MSCs or adipose-tissue-derived stromal cells (ASCs) accelerates skin-wound healing in nude 
mice [1]. Similarly, results of clinical trials have demonstrated the benefits derived from the 
employment of both autologous or heterologous MSCs, especially in chronic wounds [25–28]. 
Defined as adult multipotent cells, MSCs can be easily obtained from multiple sources, including 
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adipose tissue deposits localised in different areas of the body and gathered during major and/
or aesthetic surgical procedures [29, 30]. Multiple mechanisms underlying the potential ability 
of both populations to influence wound repair positively have been proposed; these include 
modulation of inflammatory states, stimulation of angiogenesis, cell proliferation and fibro-
blast activity, activation and enhanced migration of keratinocytes to sites of injury in a para-
crine fashion, possible direct transdifferentiation of MSCs towards dermal lineage (including 
fibroblasts and keratinocytes) and, finally, the recruitment of host cells [25, 31, 32]. After in vivo 
administration, the immune tolerance generated by ASCs, defined as the ability to modulate 
the immune-surveillance system in the recipient, has been largely reported as their chief bio-
logical property, thus highlighting one important advantage their use brings [33, 34]. Moreover, 
cross communication between ASCs and inflammatory cells at the site of an injury is a major 
contributory factor. Soluble factors released by MSCs and ASCs, such as vascular endothelial 
growth factor, interleukin-6 or transforming growth factors, are known to regulate local cellular 
responses during cutaneous injury [24]. It has been noted that MSCs may also exert antibacte-
rial effects at the site of a wound both by secreting an antimicrobial protein, IL-37, directly and 
by influencing immune-system phagocytosis positively [24, 35]. The proliferative and transdif-
ferentiative potential of MSCs has been highlighted also in tissue-engineering-based applica-
tions, specifically with regard to skin graft reconstruction, where MSCs are employed either 
alone, as a feeder layer for keratinocytes or seeded in combination with gelatine-, collagen-/
chitosan- or fibrin polymer-based scaffolds [36–38]. Of note among suitable substrates, synthetic 
polymers have been shown to possess considerable ability to absorb and transport fluids as well 
as provide protection against bacterial exposure [39]. Other methods used to deliver MSCs to the 
wound site include injection and local or systemic administration of a range of conveyers such 
as scaffolds, matrices and human amniotic membrane grafts [40–43].
2. Novel strategies developed at Rome’s Sapienza University
Despite considerable improvements in the employment of ASCs and MSCs in skin-regenerative 
procedures, their current use is limited because of the presence of foetal bovine serum (FBS) in the 
cultures during their ex vivo expansion. According to the European Union’s Good Manufacturing 
Practice (GMP) guidelines, the employment of FBS is to be discouraged, as it is a potential source 
of zoonoses [29, 44, 45]. In the light of this, platelet lysate (PL), a haemoderivative enriched with 
soluble mitogenic factors [29, 44, 46], represents a superior alternative to FBS. Reported to enhance 
the biological stem-cell properties of ASCs, such as proliferation, clonogenic capacity and migra-
tion [28, 46, 47], PL has been also been recently shown to be capable of promoting ASC’s pluri-
potency and being committed to specific phenotypes [46–49]. Interestingly, PL, manufactured in 
injectable form or gel [8, 9, 13, 14], embedded in scaffolds or incorporated in nanoparticles, also 
represents a widely investigated clinical strategy deemed to accelerate wound healing in chronic 
ocular and diabetic dermal ulcers. Because of the large amounts of cytokines and growth factors 
contained in PL, it presents multiple and significant advantages if applied locally to skin wounds 
when seeking enhancement of angiogenesis and fibroblast migration, restoration of collagen 
synthesis and reduction of oxidative stress [46]. In addition, it has been demonstrated that PL is 
capable of re-establishing skin integrity efficiently [50].
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Recently, a GMP-compliant PL (Mesengen™, Pub. No. WO/2013/042095) has been developed 
as an adjuvant for culturing human ASCs, endothelial progenitor cells and fibroblasts [29, 46, 
51, 52].
The Mesengen™ generation method has been standardised and optimised so as to deter-
mine the amounts of cytokines and growth factors in the preparation. Importantly, potential 
fungi, viruses and bacteria known to contaminate human haemoderivatives are avoided by 
rapidly inactivating the Mesengen™ by means of a combination of a photochemical agent 
and UV radiation. A summary of the basic steps in the preparation of PL is provided in 
Figure 1. It is worth noting that researchers at Sapienza have exploited the biological and 
molecular properties of Mesengen™ by concurrently establishing a standardised protocol 
(Figure 2) to isolate and expand ex vivo ASCs from alternative fat deposits like the medias-
tinum (Figure 3) [29, 47]. Recent studies on Mesengen™ carried out by our team have also 
elucidated its ability to influence the commitment of ASCs by inducing epigenetic modifica-
tions [47] as well as positively altering the in vitro microenvironment by decreasing oxida-
tive stress [46]. These studies highlight the ability of PL to boost the biological and functional 
properties of mesenchymal-like cell populations. Therefore, it is plausible that the combi-
nation of Mesengen™ and ASCs or other progenitor-cell populations might be employed 
successfully to target wound repair and regeneration. Furthermore, PL has been reported 
to maintain its properties either as a liquid formulation or frozen, highlighting an impor-
tant clinical advantage. In the future, this approach might be considered complementary to 
routine strategies developed at Rome’s Sapienza University, where a centre of excellence for 
Figure 1. Overview of the major steps in the manufacturing of platelet lysate (Mesengen™).
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in vitro culturing of skin substitutes exists already, providing the treatment of a wide range 
of dermal disorders, such as burns, chronic ulcers, giant congenital melanocytic nevi and 
even the reconstruction of epithelial mucosa [53–58]. Specifically, the epithelial “organoid” 
developed by our research group is based on a combination of transplanted autologous cells 
seeded in biomimetic scaffolds. This methodology has been successfully established, is clini-
cally available at several hospitals collaborating with Sapienza and has already been shown 
to significantly reduce hospitalisation time and costs [59].
Figure 2. Flow diagram showing the optimization and standardisation phases to isolate and expand in vitro ASCs 
derived from the mediastinal fat depots.
Figure 3. Optical image of ASCs at passage 3 cultured in PL and displaying the typically spindle-shaped morphology 
(A). Note that platelet lysate is able to preserve the mesodermal transdifferentiation of ASCs towards the adipogenic (B), 
osteogenic (C) and chondrogenic (D) lineages. Magnification 5×.
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Our group’s experience of advanced dressings and dermal substitutes over the years dur-
ing treatment of patients with acute and chronic ulcers of multifactorial origin (arteriopathic, 
phlebopathic, immunological and traumatic) produced a study based on chronic arteriopathic 
patients, the results of which were published in the article “Wounds Difficult to Heal: An 
Effective Treatment Strategy” [60]. There we highlighted the fact that recognition of the aetiol-
ogy of a skin lesion and the correction of the pathophysiological conditions that determine 
and support it are the assumption and “step” fundamental to the success of local treatment. 
It also emerged that a “standard”, univocal treatment applicable to all and every kind of 
wound does not exist. Appropriate local treatment involves a combination of multiple medi-
cations, products and devices demanding respect of their timing and guarantees regarding 
their ongoing management.
In a very recent study we focused, instead, on the treatment of chronic phlebostatic ulcers. This 
study was conducted at the Department of Surgical Sciences of Rome’s Sapienza University 
between October 2016 and March 2018.
The purpose of that study was to assess the efficacy of using dermic substitutes when treating 
patients suffering from chronic skin ailments due to and sustained by venous insufficiency.
This examination took parameters like the following into consideration: reduction of the size 
of the wound and improvement of quality of life (QoL) as expressed subjectively, on the basis 
of a number of elective factors.
2.1. Materials and methodology
The study sample involved 13 patients suffering from chronic venous insufficiency (CVI) and 
postthrombotic syndrome, 5 of whom were also affected by pronounced varicosity, with incon-
tinence of the saphenous-femoral junction and protracted reflux of the great saphenous vein 
(GSV). Ten of the patients, before proceeding to treatment with dermal substitutes, had been 
treated surgically for phlebopathy: six had undergone “stripping” of the GSV (of the “short” in 
two cases); two patients underwent crossectomy due to recurrence accompanied by inguinal-
crural cavernoma; in five of the patients, the “feeder” veins were identified and linked, two 
of them as treatment in isolation (the other three in association with treatment for varices); 
and in the remaining three cases, the only management, besides local intervention, was elastic 
compression.
Eight other patients, initially included in the study, were excluded later on because of the 
impossibility of proceeding with the therapy in the manner set down by the team’s protocol.
The patients were chosen according to the following criteria:
• They had to be aged 50 or over.
• They had to present with chronic venous insufficiency, accompanied or not by varicosity 
of the great saphenous vein.
• Their ulcers had to have an area no greater than 20 cm2.
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The presence of undermined margins was an indication of treatment with infiltrations of 
platelet concentrate (PC) or mesenchymal (“regenerate”) cells.
The presence of wound contamination was a criterion dictating temporary exclusion although 
patients were readmitted to the study once this condition was resolved.
All the patients provided informed consent, having evaluated compliance with the proviso 
requiring their participation for the entire duration of the treatment.
The criteria for exclusion were:
• Exposure of bone or nerve, ligament or aponeurotic tissue
• The presence of immunohaematological disease
• Neoplasms and chemoradiotherapy treatment
• The use of anti-inflammatory drugs, immunosuppressant and cytostatic drugs and oral 
anticoagulants for severe comorbidity (chronic renal failure requiring dialysis, congestive 
cardiomyopathies, liver failure) and concomitant arteriopathies (mixed genesis of the ulcer)
• Poor/low self-sufficiency and/or lack of family or caregiving support, a factor mandatory 
for participation in the study
All the patients were assessed preliminarily by an ecocolor Doppler examination and other 
tests useful for inclusion/exclusion in the study. The ultrasound check sought confirmation 
of proximal saphenous-femoral valve incontinence and/or of saphenous perforators; in cases 
with referred stripping, it looked for the presence of accessory saphenoids or lapses of the 
cross (cavernoma) and, as far as deep circulation was concerned, the patency and absence 
of reflux with severe incontinence. These data, together with an objective examination, were 
the criteria adopted for preliminary surgical treatment and for the choice of local treatment 
recurring to one or more of the four dermal substitutes foreseen by the study, in some cases 
in sequence and/or in combination.
All the patients underwent local “wound bed preparation”, requiring different lengths of 
time for different patients. WBP was followed by the applications of dermal substitutes. The 
dermal substances used were autologous or homologous platelet concentrates (PC); “micro-
grafts” of autologous mesenchymal origin (“Rigenera Activa” System); “HyaloMatrix” 
PA Tissue Reconstruction Matrix (Fidia), on a hyaluronic acid base; and “Integra” Dermal 
Regeneration Template (LifeSciences Corp.), on a collagen base.
For the preparation and application of platelet concentrate, both from whole autologous and 
homologous blood, a specific protocol is followed: in the former case, the donor’s personal 
data are recorded in the Blood Transfusion Service’s management system (Emonet) which 
assigns an identification number to the donation; the blood collected is contained in a bag 
containing ACD (citrate glucose) anticoagulant, and the CP is produced by recurring to two 
centrifugation cycles: the first of these at a low rpm rate (210 g × 10 minutes) to obtain platelet-
rich plasma and eliminate the red blood cells and leucocytes and the second at a higher rpm 
rate (2000 g × 15 minutes) to concentrate the platelets by eliminating the depleted plasma. 
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The platelet concentrate should be 1 × 106/ml ± 20%. All the preparations thus obtained are 
checked for the biological validation required by law; a blood count is carried out as well as a 
microbiological test to verify their sterile state.
To keep the CP, sterile containers are used, each dose is rendered identifiable by its donation 
code; the type of the blood component and the expiry date of the product are also provided. 
All production and packaging procedures are carried out in aseptic conditions, in a sterile-
welded closed circuit or under a laminar flow hood during the phases when it is necessary to 
open the circuit. The pouches containing the CP are deposited in protective cases with labels 
bearing the same data as those indicated on each dose and stored in a freezer at −80°C.
In cases where the patient’s clinical and/or haematological conditions, the size of the ulcer and 
the number of medications to be carried out do not permit harvesting of autologous blood, 
umbilical cord or fractional blood from an adult donor is used.
To produce CP from umbilical-cord blood, cord blood units deemed unsuitable for the hae-
matopoietic stem-cell transplant bank are availed of. Cord units are considered suitable for 
the production of CP if they meet the foreseen regulatory requirements and are endorsed 
by specific informed consent as prescribed for their use. The production method used is the 
same as that described for CP obtained from whole autologous blood. For the treatment units 
compatible with the blood group of the candidate for treatment are used.
For the production of homologous fractional-blood CP, the blood component is prepared by 
collecting one or more units of single buffy-coat platelets and a bag of freshly frozen plasma, 
fractioned with blood donations free of transmissible viral diseases. The final platelet con-
centration should always be 1 × 106/ml ± 20%. The CP thus obtained is stored in the manner 
described above.
On the day of the treatment, the platelet concentrate is defrosted and activated by adding 
10% calcium gluconate (0.3 ml of Ca per ml of CP): in practice, 10 ml of the CP are placed on 
a sterile plate and mixed with 3 ml of calcium gluconate. The solution, stirred gently and left 
to rest for 10′–15′, forms the platelet gel to be placed on a sterile gauze and placed directly on 
the ulcer, making sure that it covers the entire area of the lesion.
CP gel was used on seven patients, in compliance with our protocol of one application every 
4 days for a maximum of 8 weeks (for a total of 14 dressings), in three cases homologous CP 
(with low Hb values found upon haemochromocytometric examination), and in four cases, 
autologous CPs (blood sampling of 410 cc) were considered sufficient for the applications 
foreseen.
In six patients, the “regenerate” system was used, with one application every 4–5 days, for a 
maximum of four applications, over a total of about 20 days; in three of these cases, the treat-
ment was used in association with and subsequent to CP, because it had not been possible 
to prolong the application of CP for the entire 8-week period (in the case of two patients) or 
because, at the end of the maximum number of 14 applications of the platelet concentrate, a 
completely unsatisfactory result was obtained (in the case of one patient); in the other three 
cases, after treatment with Rigenera (for a maximum of four applications over a total period 
of 3 weeks), Thiersch thin dermo-epidermal grafts were carried out.
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The “Hyalomatrix PA” dermal substitute was applied to one patient and the “Integra” dermal 
substitute to two patients. This choice was made when the patients presented a particularly 
“lively” tissue granulation phase and the size of the lesion was close to the 20-cm2 limit (the size 
of the product used being 5 × 5 cm). These patients were medicated every 3–4 days, according 
to the modalities set down in the technical data sheet, until the product was absorbed. On the 
basis of our protocol, all 13 patients were medicated every 3–7 days, monitored and observed 
for a total period of 8 weeks.
At the beginning of the study and at the end of the 8-week treatment period, in order to assess 
its efficacy, the following parameters were considered and used to define the results:
a. The extent of the reduction of the size of the ulcer
b. Patients’ subjective perception of pain according to the NRS numerical scale, a scale of 
values from 0 to 10, where 0 corresponds to absence of pain and 10 to the maximum level 
of pain perceived
c. Quality of life, this too based on patients’ subjective judgement, with reference to night-
time rest, itching, pain, need for painkillers, wet impregnation of the wound, bad smell 
and hygiene of the wound.
All these are elements that strongly impact upon life relationships and recovery of habitual 
daily activities, including work. A numerical value was attributed to each parameter, used 
together with all the others and employed to calculate overall average values.
Our study’s 13-patient sample, as shown in Table 1, included 6 females and 7 males, whose 
ages ranged between 65 and 77 (for a mean age of 71); at the beginning of the treatment, the 
maximum average diameter of the wounds was 5 cm, a range of between 3 and 6.5 cm.
2.2. Results
During the 8 weeks of treatment, some signs of improvement were observed in all patients: 
appearance in the wound bed of small islands of granulation tissue, superficialization of the 
bottom of the ulcer and growth of margin tissue. During the first 30 days, a reduction in over 
25% of the area of the wound was observed; a reduction in more than 50% was observed in 
the 10 patients who underwent preliminary surgical treatment. In the remaining three cases, 
that is, the patients subjected to elastic-compressive bandaging only, there was an average 
reduction in 45% by the end of the 8 week.
The first four patients treated with CP, obtained on average a 57.5% reduction of the wound’s 
maximum diameter. The three patients treated with a combination of CP and Rigenera achieved 
Diameters of the ulcers during the treatment
Beginning (cm) End (cm) Reduction (%) P-value
Average value 5.0 2.1 56.9 0.001
Standard deviation 1.1 0.6 7.2
Table 1. Variations of the diameters of the lesions from the beginning to the end of the treatment.
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a 60% reduction, a result just marginally better than the previous one; but one needs to keep 
in mind that these presented graver lesions are harder to manage than those of other patients. 
The three other cases, treated with Rigenera and a Thiersch graft, achieved a 55% reduction 
in the ulcer’s greatest diameter. The two patients treated with the “Integra” dermic substitute 
obtained a 52.5% diminution of the wound’s maximum diameter. Finally, the patient treated 
with the “Hyalomatrix” skin substitute achieved a 60% reduction. On the whole, by the end of 
the observation period, the average reduction of the lesion for 13 patients was 57%.
All the patients during the period of treatment reported a gradual reduction in pain, from an 
initial average of 7 on the NRS scale (range 9–5) to an average of 3 (range 6–2) at the end of 
the period (see graph 1). On the whole, the average reduction of perceived pain dropped by 4 
points on the NRS numerical scale.
At the end of the 8-week treatment period, an average of 8.25 out of 13 patients reported 
improvements in their quality of life, a spontaneous reduction in pain, a lessening of itchiness 
and secretion, lower incidence of bad odour with a recovery of functional capacity and almost 
complete resumption of habitual everyday activities. The results are summarised in Tables 1–3.
It needs to be pointed out that during the treatment period no superinfections of the wounds 
requiring interruption of the therapy arose nor did other secondary complications associated 
with the use of the products occur.
Pain (numerical rating scale)
Time 0 4 weeks 8 weeks P-value
Average value 6.9 4.3 3.2 0.001
Standard deviation 1.3 1.3 1.2
Table 2. Variations of the “pain” from the beginning to the end of the treatment.
Aggravated (A) Unmodified (B) Slightly ameliorated 
(C)
Clearly ameliorated (D)
Nocturnal rest 0 pts. 3 pts. 3 pts. 7 pts.
Itch 0 pts. 3 pts. 2 pts. 8 pts.
Pain 0 pts. 0 pts. 4 pts. 9 pts.
Need of analgesics 0 pts. 0 pts. 3 pts. 10 pts.
Mobilisation 0 pts. 3 pts. 3 pts. 7 pts.
Foul odour 0 pts. 2 pts. 2 pts. 9 pts.
Restart of daily activities 0 pts. 2 pts. 4 pts. 7 pts.
Social and relational life 0 pts. 1 pts. 3 pts. 9 pts.
Total (average values) 0 1.75 3 8.25
Table 3. Variations in QoL, stated by the patients.
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3. Perspectives and conclusions
Despite advances in wound-healing treatment, dermal tissue still remains a difficult organ 
to regenerate. Our work in the future will probably consist in multistep approaches rather 
than in single repair strategies, which have proven to be only partially efficacious. Future 
strategies will, most likely, combine stem-cell properties, next-generation scaffolds or vehicles 
(i.e. nanoparticles) and growth factors or supplements, like PL. Improvements in our under-
standing of skin biology and the physiological processes of wound repair should permit us to 
interpret healing microenvironments better. To achieve our final goal, we will be required to 
design more personalised therapies, taking into account genetic variability, wound types as 
well as patients’ clinical and metabolic features.
It is not possible, in actual fact, to reach definitive conclusions given the variability of the 
factors capable of influencing the outcome of therapy and the difficulty of rendering popula-
tions of patients treated totally homogeneous. Furthermore, this aspect also emerges from 
the field’s latest literature [60–62], being the only source available at present (since there are 
no definitive guidelines available). In addition, this kind of patient is not always willing to 
follow the lengthy periods of treatment often deemed necessary or comply with the temporal 
parameters the cure requires. Due to certain events like intercurrent pathologies, hospitalisa-
tion or logistic problems, exclusion from a study sample may become inevitable. For these 
reasons we consider the results obtained here as preliminary.
• Having said this, we are in a position to assert that skin substitutes are capable of deter-
mining a clinical improvement of chronic ulcers caused by pathologies of the vein when, 
after use of traditional medication, or accurate advanced debridement, the condition of 
the ulcer is such that regeneration of tissue is feasible. Indeed, timing seems essential for 
prescriptions as well: both precocious and tardy dressing may nullify the effectiveness of a 
treatment, jeopardising the outcome.
• The integrated use of different compounds can prove useful, especially in relation to the 
long periods often needed to obtain complete healing. Every single treatment may deter-
mine partial, even substantial, improvement but may fail to cure the lesion completely: 
there is no “ideal” medication for all ulcers, just as there is no “ideal” medication applicable 
to all the developmental stages of an ulcer.
• The specific treatment of comorbidities and restoration of a satisfactory level of nutrition 
are of great importance when pursuing positive outcomes of any local therapy, though 
chances of complete success are related mainly to a correct diagnosis regarding the origin 
of the ulcer and, above all, the removal, surgical if necessary, of factors impeding recovery: 
“The beginning of healing lies in knowledge of the ailment” (Epicurus, 341–270 BCE).
• Dermal substitutes have become, therefore, part of the modern concept of the multidisci-
plinary approach to the treatment of chronic skin lesions, in particular, the management 
of wounds that are less likely to heal availing of standard therapy. They represent a valid 
therapeutic “step”, whether used alone or in combination, also considering the potential 
clinical benefits demonstrated and the low percentage of complications related to their use.
Wound Healing - Current Perspectives228
• The use of these substitutes does cause a reduction in the size of ulcers, improving, above 
all, the quality of life of patients. One notices, in particular, a reduction in levels of pain and 
resumption of habitual everyday activities.
• The choice of the best therapy, from among the different options available, also depends 
on the physician’s ability to perceive the one most suitable for the type and characteristics 
of the patient and the availability of his/her caregivers.
In conclusion, the numerous technological opportunities made available by regenerative 
medicine, including advanced dressings and dermal substitutes, if used correctly and follow-
ing a multidisciplinary approach if necessary, seem to offer advantages in terms of clinical 
efficacy, patients’ quality of life and, last but not least, also in terms of healthcare costs.
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